kosmos ultrasound price: EchoNous Cost Guide

Kosmos Price at a Glance

A new Kosmos sells for $7,495-$11,995 plus a $720 per year required subscription Source. That is the starting point for budgeting, not a footnote to read after procurement has already decided the device fits.

Used Kosmos units run $3,500-$6,500 on the secondary market Source. The discount is meaningful, particularly for a practice adding POCUS without a large capital budget. But a used-device listing only answers one part of the buying question: what the seller wants for the hardware.

You also need to know whether the serial number can be transferred, whether service remains available, whether software access follows the device, and whether the accessories in the listing are the accessories you need. A low used price can turn into a money pit if the system arrives without a workable path to support or software.

The Kosmos used buying guide lays out the transfer checks in more detail. Start there before treating a marketplace listing as a completed price comparison.

Kosmos has been FDA-cleared since 2019 Source. That history matters because buyers are not evaluating a speculative hardware concept. They are evaluating the current economics of an established handheld platform, including recurring service costs and a secondary market where records can be incomplete.

Price lists also tend to flatten meaningful differences. A handheld system can look expensive beside another probe, then look cheap beside a cart-based ultrasound system. The POCUS category's legacy price estimate spans $2,000-$50,000 from handheld probes to cart-based systems Source. Kosmos sits in the handheld end of that market, but it is not trying to be the bargain-bin handheld.

What the Triple-Probe Design Gets You

Kosmos is EchoNous' entry in the POCUS category, built around AI-assisted handheld ultrasound with a triple-probe design. Its intended-use scope includes cardiac, lung, abdominal, and vascular work.

That combination changes the workflow calculation. A clinician does not have to frame Kosmos as a device for one narrow bedside question. The system is built for teams that want to move among common scanning needs without treating each exam type as a separate equipment purchase.

Cardiac work is where many buyers will focus first. EchoNous positions Kosmos around an AI-assisted workflow, which can be attractive for clinicians developing confidence with image acquisition and interpretation support. The device still does not remove the need for clinical judgment, appropriate training, or a clear protocol for what happens after an abnormal scan. It can make the path from bedside question to usable image less cumbersome.

Lung scanning adds another routine use case. In acute, inpatient, and clinic settings, lung POCUS can become part of a repeated assessment workflow rather than a one-off event. A device that is already available for cardiac work may see more use when it also fits that routine.

Abdominal and vascular scanning widen the case for carrying a single handheld system. The value is not theoretical versatility. It is fewer interruptions when the clinical question changes. A patient who begins with one concern does not always remain one concern after the exam starts.

This is where device specifications become operational. A cheaper probe may be the correct choice for a team with a tightly defined use case. A broader system makes more sense when the same clinicians expect to scan across cardiac, lung, abdominal, and vascular indications. Buying the wrong scope to save money is a familiar kind of false economy.

AI assistance belongs in that same practical frame. It may help support acquisition and workflow, but it does not turn POCUS into an autopilot. Clinics still need governance, image documentation, training expectations, escalation paths, and a realistic view of who will use the device. Hardware gets approved once. Workflow gets tested every day.

Kosmos has been FDA-cleared since 2019 Source. For buyers, that is useful context when weighing a device that combines portability with a wider intended-use scope than a single-purpose tool.

The Required Subscription, Explained

A new Kosmos sells for $7,495-$11,995 plus a $720 per year required subscription Source. The word “required” deserves more attention than it usually gets in product comparisons.

The device price is the upfront commitment. The subscription is part of the ongoing cost of keeping the system supported. If a clinic budgets only for the hardware, it has not budgeted for Kosmos.

Service and warranty are included in the $720 annual subscription Source. That gives the recurring fee a concrete role. It is not just a software line item hanging off the side of the purchase. It covers support and warranty protection that a clinical device buyer would otherwise need to price separately or accept as a risk.

That does not mean every buyer should accept the recurring cost without scrutiny. It means the comparison should be honest. Ask what service access looks like, what warranty coverage applies, how software access is handled, and what happens if the device changes hands. Then compare the total operating model against alternatives rather than comparing only the opening invoice.

For a used purchase, this becomes more important. Used Kosmos units run $3,500-$6,500 on the secondary market Source. The lower hardware price may be compelling, but it is only compelling if the buyer can verify service eligibility, software access, training access, accessories, warranty status, recall status, title, and serial-number transfer.

A seller may have a clean-looking unit and incomplete paperwork. Those are different things.

The Kosmos cost breakdown is the better place to work through device cost, recurring cost, and ownership questions side by side. Procurement teams often need that detail. Individual clinicians should want it too, especially when they are making the case internally.

The legacy editorial profile for Kosmos should also be treated as a buyer's-guide record rather than a substitute for current vendor documentation. Confirm current commercial terms directly before signing anything. Regulatory and claim-level reconciliation remains pending, so verify the configuration, service eligibility, and intended use for the specific unit under consideration.

Kosmos vs Other Handheld POCUS Devices

A competing Butterfly iQ+ probe is estimated at $2,499-$3,999 new Source. On upfront device price alone, that creates a clear gap between Butterfly iQ+ and a new Kosmos.

A new Kosmos sells for $7,495-$11,995 plus a $720 per year required subscription Source. A competing Butterfly iQ+ probe is estimated at $2,499-$3,999 new Source. Kosmos therefore asks buyers to justify a higher entry cost through its broader triple-probe design, AI-assisted workflow, and the way it fits their clinical practice.

The cheapest handheld is often the winner for a clinician who needs one focused capability and will use it often. That buyer should be skeptical of paying for scope they will not use. A device gathering dust in a drawer is expensive at any price.

Kosmos has a stronger argument for a clinic that wants one portable system to cover cardiac, lung, abdominal, and vascular work. In that setting, the question becomes whether one multi-use device reduces enough friction to earn the premium. The answer depends on case mix, training, existing imaging access, and who owns the device after it arrives.

The category comparison can also mislead if handheld systems are judged against cart-based machines as though they solve identical problems. The POCUS category's legacy price estimate spans $2,000-$50,000 from handheld probes to cart-based systems Source. Handheld POCUS wins on portability and proximity to the patient. Cart-based systems can win when a department needs a different imaging setup, a different workflow, or a different clinical standard.

A useful buying process starts with the clinical questions your team asks most often. Then identify who will scan, where they will scan, what documentation they need, and whether they need a device that travels between settings. The device should follow the workflow, not the other way around.

For a direct handheld comparison, see the Butterfly iQ+ cost guide and the POCUS category overview. The spread across the category is wide enough that “handheld ultrasound” is not a sufficient purchasing category by itself.

Buying Notes Before You Commit

Kosmos is best evaluated as a system purchase. The device, subscription, service coverage, warranty, accessories, software access, and training all affect whether it works in practice.

Start with the new-unit quote. A new Kosmos sells for $7,495-$11,995 plus a $720 per year required subscription Source. Ask the seller to state the device configuration, included accessories, subscription terms, service coverage, warranty coverage, and any training provisions in writing.

If you are considering used equipment, ask for the serial number before money changes hands. Used Kosmos units run $3,500-$6,500 on the secondary market Source. Verify title, recall status, service eligibility, software access, training, accessories, and warranty after transfer. If any of those answers are vague, the discount needs to be large enough to justify the risk. Often it is not.

Then test the clinical fit. Kosmos has been FDA-cleared since 2019 Source, with intended-use scope across cardiac, lung, abdominal, and vascular work. That is a useful breadth for a team that expects to scan across those applications. It is less compelling for a buyer whose use case remains narrow.

The buyer-kit checklist should sit alongside this decision: identify the users, define the exam types, assign image-review responsibility, document the escalation path, and determine who owns subscription renewal. Those questions are less glamorous than a device demo. They are also where a good purchase turns into a usable program.